Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$46.83 -0.4%	$47.78	$39.35 ▼ $63.33	$95.27B	0.36	13.50 million shs	1.33 million shs
GSK GSK	$38.04 -1.2%	$38.97	$31.72 ▼ $44.67	$77.87B	0.5	5.20 million shs	646,568 shs
REGN Regeneron Pharmaceuticals	$549.10 +0.2%	$551.63	$476.49 ▼ $1,211.20	$59.32B	0.33	901,867 shs	52,394 shs
ZTS Zoetis	$158.47 -0.4%	$160.92	$139.70 ▼ $200.33	$70.51B	0.91	3.01 million shs	239,292 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.32%	+1.95%	-2.29%	-17.44%	+17.75%
GSK GSK	-1.03%	+0.65%	-7.46%	-1.30%	+0.82%
REGN Regeneron Pharmaceuticals	+2.40%	+5.28%	+11.60%	-10.30%	-47.57%
ZTS Zoetis	0.00%	+1.07%	-6.05%	-0.16%	-8.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9226 of 5 stars	3.2	3.0	4.2	4.0	3.4	3.3	1.3
GSK GSK	2.046 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5
REGN Regeneron Pharmaceuticals	4.9395 of 5 stars	4.4	5.0	1.7	2.3	2.7	1.7	1.9
ZTS Zoetis	4.832 of 5 stars	3.5	5.0	4.2	0.4	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.85% Upside
GSK GSK	2.10	Hold	$37.38	-1.76% Downside
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	48.16% Upside
ZTS Zoetis	3.00	Buy	$212.13	33.86% Upside

Current Analyst Ratings Breakdown

Latest GSK, ZTS, BMY, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00
6/2/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$958.00 ➝ $755.00
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$662.00
5/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$700.00 ➝ $580.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.97	$5.80 per share	8.07	$8.08 per share	5.80
GSK GSK	$40.10B	1.94	$5.45 per share	6.98	$8.07 per share	4.71
REGN Regeneron Pharmaceuticals	$14.20B	4.17	$46.93 per share	11.70	$268.50 per share	2.05
ZTS Zoetis	$9.26B	7.62	$7.04 per share	22.51	$10.57 per share	14.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.53	7.69	1.41	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.61	8.18	1.36	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.99	14.44	1.96	31.94%	15.27%	11.93%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.43	23.48	2.64	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest GSK, ZTS, BMY, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.30%	N/A	92.88%	17 Years
GSK GSK	$1.69	4.44%	N/A	87.11%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.64%	N/A	8.96%	N/A
ZTS Zoetis	$2.00	1.26%	N/A	35.91%	14 Years

Latest GSK, ZTS, BMY, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
GSK GSK	1.21	0.87	0.58
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GSK GSK	15.74%
REGN Regeneron Pharmaceuticals	83.31%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
GSK GSK	10.00%
REGN Regeneron Pharmaceuticals	7.02%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

GSK, ZTS, BMY, and REGN Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Palisade Capital Management LP

1 hour ago | marketbeat.com

Summit Place Financial Advisors LLC Buys 1,755 Shares of Zoetis Inc. (NYSE:ZTS)

2 hours ago | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Principal Financial Group Inc.

2 hours ago | marketbeat.com

ZTS | Zoetis Inc. Annual Income Statement | MarketWatch

2 hours ago | marketwatch.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Tandem Investment Advisors Inc.

3 hours ago | marketbeat.com

Keybank National Association OH Sells 17,219 Shares of Zoetis Inc. (NYSE:ZTS)

5 hours ago | marketbeat.com

DAVENPORT & Co LLC Sells 18,420 Shares of Zoetis Inc. (NYSE:ZTS)

July 3 at 5:18 AM | marketbeat.com

Zoetis: Growth To Continue Thanks To Companion Animals

July 3 at 2:36 AM | seekingalpha.com

ZTS - Zoetis Inc Class A Executives - Morningstar

July 2 at 3:52 PM | morningstar.comM

2 of Wall Street’s Favorite Stocks to Research Further and 1 to Question

July 2 at 10:50 AM | finance.yahoo.com

2,305 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Horizon Financial Services LLC

July 2 at 9:31 AM | marketbeat.com

Here's Why Zoetis (ZTS) is a Strong Growth Stock

July 1 at 10:45 AM | zacks.com

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

July 1 at 9:02 AM | businesswire.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Summit Trail Advisors LLC

July 1 at 8:47 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

July 1 at 8:38 AM | marketbeat.com

Vontobel Holding Ltd. Has $279.75 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 1 at 7:44 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Kampmann Melissa S.

July 1 at 7:24 AM | marketbeat.com

Hixon Zuercher LLC Buys New Shares in Zoetis Inc. (NYSE:ZTS)

July 1 at 7:05 AM | marketbeat.com

New York State Teachers Retirement System Has $61.81 Million Holdings in Zoetis Inc. (NYSE:ZTS)

July 1 at 5:18 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Amalgamated Bank

July 1 at 5:08 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Has $11.18 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 1 at 4:34 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, ZTS, BMY, and REGN Company Descriptions

Bristol Myers Squibb NYSE:BMY

$46.83 -0.18 (-0.38%)

As of 10:20 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$38.04 -0.47 (-1.21%)

As of 10:20 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Regeneron Pharmaceuticals NASDAQ:REGN

$549.10 +1.36 (+0.25%)

As of 10:20 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zoetis NYSE:ZTS

$158.47 -0.61 (-0.38%)

As of 10:20 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time